TransMedics Group, Inc. (NASDAQ:TMDX) Shares Sold by Victory Capital Management Inc.

Victory Capital Management Inc. decreased its stake in TransMedics Group, Inc. (NASDAQ:TMDX) by 59.8% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 4,239 shares of the company’s stock after selling 6,294 shares during the period. Victory Capital Management Inc.’s holdings in TransMedics Group were worth $335,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Cutler Group LLC CA boosted its holdings in shares of TransMedics Group by 600.0% in the 3rd quarter. Cutler Group LLC CA now owns 700 shares of the company’s stock valued at $38,000 after buying an additional 600 shares in the last quarter. RiverPark Advisors LLC acquired a new position in shares of TransMedics Group in the 3rd quarter valued at $60,000. Van ECK Associates Corp boosted its stake in TransMedics Group by 39.0% during the 3rd quarter. Van ECK Associates Corp now owns 2,127 shares of the company’s stock worth $116,000 after purchasing an additional 597 shares during the period. Headlands Technologies LLC acquired a new stake in TransMedics Group during the 3rd quarter worth $180,000. Finally, Yarbrough Capital LLC acquired a new stake in TransMedics Group during the 4th quarter worth $201,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Stock Up 2.0 %

Shares of TransMedics Group stock opened at $140.29 on Friday. The company has a market cap of $4.62 billion, a P/E ratio of -412.62 and a beta of 1.87. The company has a debt-to-equity ratio of 3.18, a quick ratio of 8.76 and a current ratio of 9.72. TransMedics Group, Inc. has a one year low of $36.42 and a one year high of $142.78. The firm has a fifty day moving average of $100.95 and a two-hundred day moving average of $86.81.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Tuesday, April 30th. The company reported $0.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.40. The business had revenue of $96.90 million during the quarter, compared to the consensus estimate of $83.78 million. TransMedics Group had a negative net margin of 3.43% and a positive return on equity of 7.95%. The business’s revenue was up 132.9% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.08) EPS. On average, analysts forecast that TransMedics Group, Inc. will post 0.76 earnings per share for the current year.

Insider Activity

In other news, insider Tamer I. Khayal sold 10,000 shares of the stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $82.99, for a total value of $829,900.00. Following the completion of the transaction, the insider now owns 26,502 shares in the company, valued at approximately $2,199,400.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider Tamer I. Khayal sold 10,000 shares of the stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $82.99, for a total value of $829,900.00. Following the completion of the transaction, the insider now owns 26,502 shares in the company, valued at approximately $2,199,400.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Waleed H. Hassanein sold 12,000 shares of the stock in a transaction dated Wednesday, April 10th. The shares were sold at an average price of $95.09, for a total transaction of $1,141,080.00. Following the completion of the transaction, the chief executive officer now owns 74,087 shares of the company’s stock, valued at approximately $7,044,932.83. The disclosure for this sale can be found here. Insiders sold 297,363 shares of company stock worth $31,855,794 in the last 90 days. 7.00% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages recently weighed in on TMDX. Oppenheimer increased their price target on shares of TransMedics Group from $105.00 to $125.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 1st. TD Cowen increased their price target on shares of TransMedics Group from $100.00 to $130.00 and gave the stock a “buy” rating in a research note on Wednesday, May 1st. Morgan Stanley increased their price target on shares of TransMedics Group from $75.00 to $95.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 28th. JPMorgan Chase & Co. increased their price target on shares of TransMedics Group from $105.00 to $127.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 1st. Finally, Piper Sandler restated an “overweight” rating and set a $120.00 price objective (up previously from $95.00) on shares of TransMedics Group in a research report on Wednesday, May 1st. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, TransMedics Group presently has a consensus rating of “Moderate Buy” and a consensus target price of $119.00.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.